

ORAL PRESENTATION

Open Access

Beyond late gadolinium enhancement: the key role of diffuse myocardial fibrosis in severe aortic stenosis - an Equilibrium Contrast CMR study

Andrew S Flett^{1*}, Dan M Sado¹, Giovanni Quarta¹, Olivier Huttin¹, Derek Hausenloy¹, Sanjay M Banyersad¹, David Lawrence¹, Denis Pellerin¹, Christopher McGregor¹, Andrew M Taylor², James C Moon¹

From 2011 SCMR/Euro CMR Joint Scientific Sessions
Nice, France. 3-6 February 2011

Background

In severe aortic stenosis (AS), hemodynamics and conventional indices do not fully explain symptoms, prognosis or treatment response. We hypothesize that diffuse myocardial fibrosis (DMF) is a key missing factor in AS. This can now be accurately measured non-invasively using equilibrium contrast CMR (EQ-CMR) [1] involving a primed gadolinium infusion, T1 measurement pre- and post-infusion, and direct measure of blood volume of distribution (1-hematocrit). The derived myocardial volume of distribution ($V_{d(m)}$) correlates strongly with histological diffuse myocardial

fibrosis in AS and this calibration can convert $V_{d(m)}$ to DMF%. Cell volume can be calculated as $1 - \text{DMF}\% \times \text{LV mass}$.

Methods

63 severe AS patients with planned valve replacement underwent baseline and follow up EQ-CMR. Twenty normal controls were included. Baseline and follow-up assessment included NYHA, ECG, echocardiography (for diastolic function and valve area/velocities), BNP and six minute walk test (6MWT). Follow up was at 6-months (2 declined, 4 late deaths, 13 pacemakers,




Figure 1 Relationship of DMF with 6MWT and NYHA class.

¹The Heart Hospital, London, UK
Full list of author information is available at the end of the article




Figure 2 LVH regression redefined by EQ-CMR.

11 outstanding, leaving 33). EQ-CMR results were expressed as $Vd_{(m)}/DMF\%$ (continuous variable or severity tertiles), or cell volume.

Results

Baseline

AS patients had more fibrosis than controls ($Vd_{(m)}$: 0.27 ± 0.04 vs 0.24 ± 0.04 ; DMF: 17% vs 11%, $p = 0.003$) with a wide range ($Vd_{(m)}$: 0.20-0.39; DMF: 4-42%). Breathless patients had more DMF (NYHA class III/IV vs I/II: $Vd_{(m)}$: 0.32 ± 0.03 vs 0.26 ± 0.04 ; DMF: 15% vs 27%, $p < 0.001$). DMF correlated with 6MWT (inversely, figure 1, $r^2 = 0.22$, $p = 0.001$) and aortic valve area ($r^2 = 0.21$, $p = 0.001$). DMF only correlated with EF in patients with LV impairment ($n = 15$, $r^2 = 0.47$, $p = 0.01$). Severe DMF patients had worse diastolic function ($p = 0.029$). In a multivariate analysis of all parameters classically associated with 6MWT distance, the only independent predictor was DMF ($p = 0.04$). On univariate analysis there was a weak correlation with BNP and age.

Follow up

Overall, patients improved at follow-up (6MWT, EF, BNP, LV mass, LV volumes). However, only patients with severe fibrosis improved their exercise capacity ($p = 0.03$). LVH regression (202g vs 183g, $p = 0.002$) was shown to be cellular (161g vs. 142g, $p < 0.001$) rather than fibrosis (36g vs 34g $p = 0.572$) resolution, figure 2.

Conclusion

In this first clinical EQ-CMR study of severe AS, DMF is higher when there is LV impairment, diastolic dysfunction and more severe stenosis. DMF is the single best predictor of pre-op exercise capacity and post-op improvement. EQ-CMR shows that at 6-month post valve replacement LVH regression is predominantly reduced cell rather than fibrosis volume. EQ-CMR for

the non-invasive measurement of DMF appears to be a significant cardiological advance.

Author details

¹The Heart Hospital, London, UK. ²Great Ormond Street Hospital for Children, London, UK.

Published: 2 February 2011

Reference

1. *Circulation* 2010, **122**:138-144.

doi:10.1186/1532-429X-13-S1-O39

Cite this article as: Flett et al.: Beyond late gadolinium enhancement: the key role of diffuse myocardial fibrosis in severe aortic stenosis - an Equilibrium Contrast CMR study. *Journal of Cardiovascular Magnetic Resonance* 2011 **13**(Suppl 1):O39.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

